2-[6-(diethylcarbamoyl)-8-methoxy-7-methylidene-3,4,5,6-tetrahydro-2H-1-benzazonin-1-yl]ethyl methanesulfonate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-[6-(diethylcarbamoyl)-8-methoxy-7-methylidene-3,4,5,6-tetrahydro-2H-1-benzazonin-1-yl]ethyl methanesulfonate
• 化学式: C₂₂H₃₄N₂O₅S
• 分子量: 438.6
• InChiKey: REGWPUOIYQTHSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  84.5
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES<br/>[FR] PROCÉDÉ DE CRISTALLISATION DE DÉRIVÉS D'INDOLE TRICYCLIQUES
  申请人：GE HEALTHCARE LTD

  公开号：WO2014083113A1

  公开（公告）日：2014-06-05

  The present invention relates to a composition comprising a tricyclic indole compound. The composition has a higher purity and better impurity profile than known compositions comprising said tricyclic indole compound and as a consequence has superior properties, particularly when said compound is destined for use in vivo as a therapeutic or diagnostic agent. Also provided by the present invention is a method to make the composition of the invention, a pharmaceutical composition comprising the composition of the invention, and use of the composition of the invention in a medical method.